AI주식인사이트AI Stock Insight
B

아이진

185490KOSDAQ자연과학 및 공학 연구개발업

63.8 / 100

Reference Date: 2026-07-24

Financial Score23.5 / 40
News Sentiment21.3 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Surged 15.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Ajin is a biotech venture company focused on R&D in medicine and pharmacy, specializing in the development of next-generation innovative therapies such as mRNA-based vaccines and AAV gene therapies. The company is also advancing revenue-generating projects, including meningococcal vaccines and botulinum toxin development, while investing in promising ventures to secure key technologies.

Number of Employees

49people

Average Salary

58.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 43.644.0Point
PBR
1.20Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE
-36.31Industry Average -32.093.5Point

In line with industry avg

Debt Ratio
7.00Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲38.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -30.8% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 1,507Won52-week high 2,97852-week low 1,193
1-month return6.0Point

1m +15.75% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0